EisnerAmper’s Life Sciences practice offers innovators and entrepreneurs the expertise, resources and relationships they need to bridge the gaps between creativity, funding needs, and commercial success. Our Catalyst newsletter delivers timely, informative content that covers both the business and technical issues in the life science sector.

EisnerAmper is actively involved in and supports organizations such as BIO, BioNJ and PennsylvaniaBio, and has affiliations with leading academic entities such as New York University.

To get the most up-to-date information on hot topics in the life sciences industry, sign up to receive our email newsletter.

Articles January 22, 2020 How 2019 FinTech Trends May Have Laid the Groundwork for Another Roaring Twenties

A discussion of the current state of fintech as it became ever more evident that the financial industry is destined to become an amalgamation of finance and technology.

Articles January 22, 2020 A Look into Biotech and Data

A discussion of bioinformatics and computational biology, relevant developments, and the outlook for each.

Articles March 27, 2018 3D Printing Puts the "Tech" in Biotech

The 3D printing industry is estimated to grow to approximately $6 billion by 2024. Prosthetics, knee and hip replacements, implants, hearing aids, tissue and medicines are expected to drive 3D-printed biotech products.

Articles March 27, 2018 Four Gross-to-Net Pitfalls to Avoid

Companies should also develop detailed analytics to understand trends and the magnitude and appropriateness of customer pricing adjustments. The most successful companies use a combination of in-house technology and third-party resources.

Articles December 18, 2017 Words of Wisdom from a Biotech M&A Pro

Life science companies pursue strategic transactions in several forms, primarily to access various types of capital necessary to effectively compete in the global biopharmaceutical sector. Why are strategic acquisitions popular with life science comp…

Articles September 29, 2017 Can Biotechs Use a Virtual Model to Combat R&D Costs?

Biotech companies are looking for innovative ways to curtail some of the heavy R&D financial burden. The virtual company model presents a potential avenue for biotechs to mitigate some of these enormous costs.

Articles September 29, 2017 How Life Science Companies Can Benefit from the R&D Tax Credit Now

The PATH Act included various changes to the R&D credit related to payroll taxes and the alternative minimum tax (AMT) that are tremendously beneficial for biotech firms - particularly start-ups and small businesses.

Articles June 12, 2017 The Financial Impact of Biotech Product Launch Delays, and the Consequences of Not Having a Bridging Strategy

Proper management of product launches is essential to minimize negative financial impacts. Successfully developing and implementing a bridging strategy can lead to increased coordination efforts.

Articles June 12, 2017 Is Biotech Globalization Worth the Investment?

For U.S.-based biotech companies, the question is does globalization still make sense? The life science industry is already facing numerous challenges, including varying regulatory and pricing pressures throughout the world.